DT-109, a glycine-based tripeptide The dominant search intent for "dt 109 peptide" is to understand what the compound is, its demonstrated effects, and its potential therapeutic applications, particularly in the areas of liver disease and atherosclerosis.DT-109 - Induces glutathione biosynthesis, AMS.MC-5732-2
Tier 1 Entities & Phrases:
* dt 109 peptide
* DT-109
* tripeptide
* glycine-based tripeptide
* nonalcoholic steatohepatitis (NASH)
* fatty liver disease
* atherosclerosis
* reversed hepatic steatosis
* prevented fibrosis progression / scarring
* reduced atherosclerotic lesion formation
Tier 2 Entities & Phrases:
* Gly-Gly-Leu (specific tripeptide composition)
* orally active peptide
* reduces blood glucose levels
* lowered circulating glucose, lipids, transaminases, and proinflammatory cytokines
* glutathione biosynthesis
* Diapin Therapeutics
* University of Michigan researchers
* animal models (mice, nonhuman primates)
* oral glucose tolerance test (OGTT)
* GLP-1 and insulin levels
Tier 3 Entities & Phrases:
* DT-109peptidefor sale (commercial intent, not yet supported by general research findings)
* DT-109 drug (too general)
* DT-109 clinical trial (no direct evidence in provided snippets)
---
The dt 109 peptide, specifically a glycine-based tripeptide known as DT-109, has emerged as a compound with significant therapeutic potential, particularly in addressing nonalcoholic steatohepatitis (NASH) and atherosclerosis. Research indicates that DT-109 is capable of not only reversing established liver conditions but also mitigating arterial plaque formation, suggesting a dual benefit for metabolic and cardiovascular health1天前—In this study, bifunctionalpeptideswith potent trypsin-inhibitory activity and antimicrobial activity were obtained by rational computation- .... This peptide, composed of three amino acids, is orally active and has demonstrated remarkable efficacy in preclinical studies involving animal models.Recent advances of hepatoprotective peptides: Production, structure ...
DT-109 is identified as a tripeptide, with specific research pointing to its composition as Gly-Gly-Leu. Its glycine-based structure appears central to its biological activity. Studies suggest that DT-109 functions by influencing key metabolic pathways2023年4月10日—Results reveal thatDT-109reversed fat buildup and prevented scarring in the livers of both mice and primates that had developed NASH. The .... For instance, it has been shown to enhance glutathione biosynthesis, a critical antioxidant process within the liver, and to stimulate fatty acid degradation. These actions collectively contribute to its ability to reverse hepatic steatosis—the buildup of fat in the liver—and prevent the progression of fibrosis and inflammation associated with NASH.2025年5月13日—Researchers at the University of Michigan have developed DT-109, a compound thatreduces fatty liver disease and atherosclerosis.
The most extensively documented application of DT-109 is in the treatment of fatty liver disease, including its more severe form, nonalcoholic steatohepatitis (NASH)DT-109 ameliorates nonalcoholic steatohepatitis in .... Preclinical trials, particularly in nonhuman primates and mice, have yielded compelling results. DT-109 has been observed to reverse hepatic steatosis and, crucially, to prevent the scarring or fibrosis that can lead to irreversible liver damage and liver failure. By targeting the underlying metabolic dysregulation, DT-109 offers a promising avenue for managing these increasingly prevalent liver conditions.
Beyond its liver-protective effects, DT-109 has demonstrated a significant impact on atherosclerosis, a primary driver of cardiovascular mortality. Research indicates that DT-109 administration significantly suppressed atherosclerotic lesion formation in the aorta and coronary arteries of animal models. This suggests that the peptide’s benefits extend to the cardiovascular system, potentially by reducing systemic inflammation, improving lipid profiles, and positively influencing vascular health.DT-109 shows promise in treating atherosclerosis and liver ... The ability to address both liver disease and arterial plaque formation positions DT-109 as a potential multi-target therapeutic.Glycine-Based Tripeptide Treats Severe Form of Fatty Liver ...
Further investigations into the effects of DT-109 have revealed its capacity to influence broader metabolic parameters. The tripeptide effectively lowered blood glucose levels in various type 2 diabetes mouse models, partly by increasing levels of GLP-1 and insulin. Additionally, DT-109 has been noted to lower circulating glucose, lipids, transaminases, and proinflammatory cytokines. These findings underscore its potential role in managing metabolic syndrome and related disorders, offering a comprehensive approach to improving overall health.
DT-109 was initially developed by researchers at the University of Michigan and is being explored by companies like Diapin TherapeuticsDT-109 | Induces glutathione biosynthesis. Its status as an orally active peptide is a significant advantage, simplifying administration compared to injectable therapeutics. While current evidence stems primarily from preclinical studies, the consistent and positive outcomes in reversing liver disease and reducing atherosclerosis in animal models highlight its considerable therapeutic promiseDT-109 (CAS 14857-82-0). Further research and clinical trials will be crucial to validate these findings and pave the way for its potential use in human medicine.
In conclusion, the dt 109 peptide represents a noteworthy advancement in the search for effective treatments for NASH and atherosclerosis. Its demonstrated ability to reverse fat buildup and prevent scarring in the liver, alongside its capacity to reduce atherosclerotic lesions, marks it as a compound of significant interest for both liver health and cardiovascular disease management.
Join the newsletter to receive news, updates, new products and freebies in your inbox.